The Technology team guided Triomics on raising $22 million in Series B financing led by Battery Ventures, with participation from existing investors Nexus Venture Partners, Lightspeed, and Y Combinator, alongside strategic backers Oncology Ventures and Precision Health Informatics, a wholly owned subsidiary of Texas Oncology. This round brings Triomics' total funding raised to date to more than $36 million. The new capital will be used to accelerate adoption across health systems, oncology networks, and life sciences organizations; grow Triomics' AI/engineering and forward-deployed teams; and advance the company's AI agents for clinical care and research.
Triomics is an oncology AI company building the infrastructure that turns complex, longitudinal cancer records into structured, explainable intelligence. The company's platform supports patient trial matching, pre-visit chart prep, and oncology data abstraction, helping care teams, research teams, and health systems act faster on the information already in the chart. Headquartered in New York, Triomics is backed by Battery Ventures, Lightspeed, Nexus Venture Partners, Y Combinator, and Oncology Ventures.
The Goodwin team was led by Andrew Harper, Shaika Ahmed, Mira Pranav, Evelynn Chun, Christian Fan, Ginggi Storer, Ashley Shultz, Monica Patel, Jacob Osborn, Justin Pierce, Charles Li, Nate Cunningham, Gabe Maldoff, Matthew Wetzel, and Ora Grinberg with invaluable assistance from Will Rixmann and Maggie Wong.
For more information on the deal, please read the press release.